Advertisement

PentaVision

Retinal Physician

Article | 2025 ARVO Meeting

EYP-1901 Shows 9-Month Disease Control in NPDR Patients

Despite missing the 12-month primary endpoint in PAVIA, the implant demonstrated early efficacy, guiding design for a planned phase 3 trial.

By: Jim Gallagher, senior managing editor
Retinal Physician May 8, 2025

Clinical Scorecard: EYP-1901 Shows 9-Month Disease Control in NPDR Patients

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingClinical trial setting, specifically the PAVIA trial.

Key Highlights

  • Treatment effect observed to last about 9 months post-injection, with no statistically significant improvement at 12 months.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Assess treatment effects at 6 months and 12 months post-injection, with consideration for monitoring beyond 12 months.

      Risks

        Patient & Prescribing Data

        EYP-1901 shows a trend of improvement in DRSS scores, particularly at higher doses, though not statistically significant.

        Clinical Best Practices

        • Evaluate patient response to EYP-1901 at multiple time points.
        • Prepare for potential need for retreatment after 9 months, considering patient-specific factors.

        References